Long-term retention of 177Lu/177mLu-DOTATATE in patients investigated by γ-spectrometry and γ-camera imaging

Journal of Nuclear Medicine

Volumn 56, Issue 7, 2015, Pages 976-984

  Gleisner, Katarina Sjögreen ^a   Brolin, Gustav ^a   Sundlöv, Anna ^a   Mjekiqi, Edita ^a,b   O'Stlund, Karl ^c   Tennvall, Jan ^a   Larsson, Erik ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c LUND UNIVERSITY   (Sweden)

Author keywords

177Lu; Dosimetry; Peptide receptor radiotherapy

Indexed keywords

LUTETIUM 177; LUTETIUM 177M; OCTREOTATE[0 TETRAXETAN 3 TYROSINE]LU 177; OCTREOTATE[0 TETRAXETAN 3 TYROSINE]LU 177M; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; (177LUTETIUM-DOTA(O)TYR3)OCTREOTATE; LUTETIUM; OCTREOTIDE; ORGANOMETALLIC COMPOUND; RECEPTOR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSIMETRY; GAMMA CAMERA; GAMMA SPECTROMETRY; HUMAN; KIDNEY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIATION DETECTOR; RADIOACTIVITY; RADIOISOTOPE DECAY; SPLEEN; ANALOGS AND DERIVATIVES; CHEMISTRY; FEMALE; GAMMA RADIATION; IMAGE QUALITY; MALE; NEUROENDOCRINE TUMORS; PROCEDURES; RADIATION RESPONSE; RADIOMETRY; SPECTROPHOTOMETRY; TIME;

FEMALE; GAMMA CAMERAS; GAMMA RAYS; HUMANS; KIDNEY; LUTETIUM; MALE; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; PHANTOMS, IMAGING; RADIOISOTOPES; RADIOMETRY; RECEPTORS, PEPTIDE; SPECTROPHOTOMETRY; SPLEEN; TIME FACTORS;

EID: 84936747451     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.155390     Document Type: Article

References (16)

1. Bodei L, Kidd M, Paganelli G, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: The value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015;42:5-19.
2. Garkavij M, Nickel M, Sjogreen-Gleisner K, et al. 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy. Cancer. 2010;116(4, suppl):1084-1092.
3. Kondev FG. Nuclear data sheets for A5177. Nucl Data Sheets (NY NY). 2003;98:801-1095.
4. NuDat 2.6. National Nuclear Data Center website. http://www.nndc.bnl.gov/nudat2/. Accessed May 28, 2015.
5. Knoll GF. General properties of radiation detectors. In: Radiation Detection and Measurement. Hoboken, NJ: John Wiley & Sons; 2010.
6. Fleming JS. A technique for the absolute measurement of activity using a gamma camera and computer. Phys Med Biol. 1979;24:176-180.
7. Thomas SR, Maxon HR, Kereiakes JG. In vivo quantitation of lesion radioactivity using external counting methods. Med Phys. 1976;03:253-255.
8. Hubbell JH, Coursey JS, Hwang J, Zucker DS. Bibliography of Photon Total Cross Section (Attenuation Coefficient) Measurements (Version 2.3). Gaithersburg, MD: National Institute of Standards and Technology; 2003.
9. Gleisner KS, Ljungberg M. Patient-specific whole-body attenuation correction maps from a CT system for conjugate-view-based activity quantification: method development and evaluation. Cancer Biother Radiopharm. 2012;27:652-664.
10. Sjögreen-Gleisner K. Scatter correction by deconvolution of planar whole-body scintillation-camera images using an image-based estimate of the signal-to-noise ratio [abstract]. Eur J Nucl Med. 2012;39(suppl 2):S313.
11. Ljungberg M, Strand SE. A Monte Carlo program for the simulation of scintillation camera characteristics. Comput Methods Programs Biomed. 1989;29:257-272.
12. Sjögreen K, Ljungberg M, Strand SE. An activity quantification method based on registration of CT and whole-body scintillation camera images, with application to 131I. J Nucl Med. 2002;43:972-982.
13. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027.
14. Snyder WS, Ford MR, Warner GG, Watson SB. "S," absorbed dose per unit cumulated activity for selected radionuclides and organs. MIRD Pamphlet No. 11. Reston, VA: Society of Nuclear Medicine; 1975.
15. Zimmerman BE, Altzitzoglou T, Antohe A, et al. Results of an international comparison for the activity measurement of 177Lu. Appl Radiat Isot. 2012;70:1825-1830.
16. Breeman WA, van der Wansem K, Bernard BF, et al. The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity. Eur J Nucl Med Mol Imaging. 2003;30:312-315.